Francisco Cajade Pascual

Mr. Francisco Cajade Pascual

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2024 in Antibiotics
Verified
Journal Article
Open access
IVIria Varela-Rey
Iria Varela-Rey
Enrique Bandín-VilarEnrique Bandín-Vilar
Enrique Bandín-Vilar
Francisco Jose Toja-CambaFrancisco Jose Toja-Camba
Francisco Jose Toja-Camba
ACAntonio Cañizo-Outeiriño
Antonio Cañizo-Outeiriño
FPFrancisco Cajade Pascual
Francisco Cajade Pascual
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Background and Objectives: The use of artificial intelligence (AI) and, in particular, machine learning (ML) techniques is growing rapidly in the healthcare field. Their application in pharmacokinetics is of potential interest due to the need to relate enormous amounts of data and to the more efficient development of new predictive dose models. The development of pharmacokinetic models based on these techniques simplifies the process, reduces time, and allows more factors to be considered than with classical methods, and is therefore of special interest in the pharmacokinetic monitoring of antibiotics. This review aims to describe the studies that use AI, mainly oriented to ML techniques, for dose prediction and analyze their results in comparison with the results obtained by classical methods. Furthermore, in the review, the techniques employed and the metrics to evaluate the precision are described to improve the compression of the results. Methods: A systematic search was carried out in the EMBASE, OVID, and PubMed databases and the results obtained were analyzed in detail. Results: Of the 13 articles selected, 10 were published in the last three years. Vancomycin was monitored in seven and none of the studies were performed on new antibiotics. The most used techniques were XGBoost and neural networks. Comparisons were conducted in most cases against population pharmacokinetic models. Conclusions: AI techniques offer promising results. However, the diversity in terms of the statistical metrics used and the low power of some of the articles make the overall assessment difficult. For now, AI-based ML techniques should be used in addition to classical population pharmacokinetic models in clinical practice.

11 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Francisco Jose Toja-CambaFrancisco Jose Toja-Camba
Francisco Jose Toja-Camba
LGLaura García-Quintanilla
Laura García-Quintanilla
LMLorena Rodríguez Martínez
Lorena Rodríguez Martínez
JTJulia Tomine
Julia Tomine
FPFrancisco Cajade Pascual
Francisco Cajade Pascual
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug antibodies with the traditional ELISA assay (Promonitor). A total of 200 serum samples were analyzed. Samples were classified into the following three different groups; sub-therapeutic range (IFX < 3 μg/mL and ADL < 5 μg/mL); therapeutic range (IFX: 3–7 μg/mL and ADL: 5–12 μg/mL) and supra-therapeutic range (IFX levels > 7 μg/mL and ADL levels > 12 μg/mL). Significant higher values were measured using the POC test (p < 0.001) for IFX results but no differences in ADL trough levels were observed (p = 0.3101). Spearman’s correlation indicated a good correlation between the two assays (rs = 0.88 for ADL and rs = 0.93 for IFX), and McNemar’s test revealed significant differences (p = 0.016) when classifying IFX samples between therapeutic and supra-therapeutic ranges but no significant differences were found among the other ranges for either IFX or ADL. These results show that we should be cautious when using these rapid measurement methods, and new targets should probably be defined for IFX when using this new analytical method.

3 September 2024 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
Francisco Jose Toja-CambaFrancisco Jose Toja-Camba
Francisco Jose Toja-Camba
GVGonzalo Hermelo Vidal
Gonzalo Hermelo Vidal
MVMaría Vidal-Millares
María Vidal-Millares
MDMaría José Durán-Maseda
María José Durán-Maseda
ARAlicia Rial-Pérez
Alicia Rial-Pérez
CMCristina Mondelo-García
Cristina Mondelo-García
Aripiprazole once-monthly (AOM) exhibits an important interindividual pharmacokinetic variability with significant implications for its clinical use. CYP2D6 and CYP3A4 highly contributes to this variability, as they metabolize aripiprazole (ARI) into its active metabolite, dehydroaripiprazole (DHA) and the latter into inactive metabolites. This study aims to evaluate the effect of CYP2D6 and CYP3A4 polymorphisms in combination and the presence of concomitant inducers and inhibitors of this cytochromes on ARI and DHA plasma concentrations in a real clinical setting. An observational study of a cohort of 74 Caucasian patients under AOM treatment was conducted. Regarding CYP2D6, higher concentrations were found for active moiety (ARI plus DHA) (AM) (67 %), ARI (67 %) and ARI/ DHA ratio (77 %) for poor metabolizers (PMs) compared to normal metabolizers (NMs). No differences were found for DHA. Ms for both CYP2D6 and CYP3A4 showed a 58 % higher AM and 66 % higher plasma concentration for ARI compared with PMs for CYP2D6 and NMs for CYP3A4. In addition, PMs for both CYP2D6 and CYP3A4 have 45 % higher DHA concentrations than NMs for both cytochromes and 41 % more DHA than PMs for CYP2D6 and NMs for CYP3A4, suggesting a significant role of CYP3A4 in the elimination of DHA. Evaluating the effect of CYPD26 and CYP3A4 metabolizing state in combination on plasma concentrations of ARI, DHA and parent-to-metabolite ratio, considering concomitant treatments with inducers and inhibitor, could optimize therapy for patients under AOM treatment.

12 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
IVIria Varela-Rey
Iria Varela-Rey
EBEnrique José Bandín-Vilar
Enrique José Bandín-Vilar
Francisco Jose Toja-CambaFrancisco Jose Toja-Camba
Francisco Jose Toja-Camba
ACAntonio Cañizo-Outeiriño
Antonio Cañizo-Outeiriño
FPFrancisco Cajade Pascual
Francisco Cajade Pascual
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Background and Objectives: The use of Artificial intelligence (AI) and, in particular, Machine Learning (ML) techniques is growing rapidly in the healthcare field. Their application in pharma-cokinetics is of potential interest due to the need to relate enormous amounts of data and to the more efficient development of new predictive dose models. The development of pharmacokinetic models based on these techniques simplifies the process, reduces time and allows more factors to be con-sidered than with classical methods, and is therefore of special interest in the pharmacokinetic monitoring of anti-biotics. This review aims to describe the studies that use AI, mainly oriented to ML techniques, to dose prediction and analyze their results in comparison with the results obtained by classical methods. Furthermore, in the review, the techniques employed and the metrics to evaluate the precision are described to improve the compression of the results. Methods: A sys-tematic search was carried out in the EMBASE, OVID and PubMed databases and the results ob-tained were analyzed in detail. Results: Of the 13 articles selected, 10 were published in the last three years. Vancomycin was monitored in 7 and none of the studies were performed on new an-tibiotics. The most used techniques were XGBoost and neural networks. Comparison was conducted in most cases against population pharmacokinetic models. Conclusion: AI techniques offer prom-ising results. However, the diversity in terms of the statistical metrics used and the low power of some of the articles make the overall assessment difficult. For now, AI-based ML techniques should be used in addition to classical population pharmacokinetic models in clinical practice.

9 June 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Marta Martínez-GuitiánMarta Martínez-Guitián
Marta Martínez-Guitián
FPFrancisco Cajade Pascual
Francisco Cajade Pascual
DCDiana Carolina Castro-Fernandez
Diana Carolina Castro-Fernandez
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
RNRuben Nogueiras
Ruben Nogueiras
CMCristina Mondelo-García
Cristina Mondelo-García
Background: Linezolid commonly causes hematologic toxicity, especially thrombocytopenia, during extended treatment. This effect is linked to the inhibition of mitochondrial protein synthesis, which impairs oxidative phosphorylation and cellular energy production. Although reduced complex IV activity has been observed in long-term therapy, the connection between treatment duration and mitochondrial dysfunction in humans remains insufficiently defined. Methods: Forty patients were included and stratified by treatment duration: 2–7 days (group 1), 8–14 days (group 2) and more than 14 days (group 3). To evaluate mitochondrial function in peripheral blood mononuclear cells (PBMCs) from patients treated with linezolid for different durations, Seahorse XF was used. To assess protein expression changes associated with mitochondrial toxicity, LC-MS/MS was used. Differentially expressed proteins were identified in R based on fold-change thresholds (|log₂FC|≥0.58) and p < 0.05, and results were visualized with volcano plots and STRING interaction networks. Results: All the groups were similar in terms of variables and characteristics. Mitochondrial respiration declined progressively with treatment duration and platelet counts showed a parallel reduction. Proteomic analysis identified one cluster of downregulated protein in group 2 of patients and two in group 3; they were involved in mitochondrial ATP synthesis—mainly subunits of complexes I and IV of the respiratory chain—supporting a concordant functional and molecular pattern of mitochondrial impairment. Conclusions: Prolonged linezolid treatment was associated with progressive mitochondrial dysfunction, as reflected by both functional assays and proteomic profiles. Concordant changes in respiration and protein expression support mitochondrial involvement in linezolid-related toxicity and suggest that, in addition to previously reported alterations in complex IV, complex I proteins may also be affected in treated patients.

29 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
Enrique Bandín-VilarEnrique Bandín-Vilar
Enrique Bandín-Vilar
AEAna Estany-Gestal
Ana Estany-Gestal
TCTeresa Cabaleiro
Teresa Cabaleiro
EREva Rial-Pensado
Eva Rial-Pensado
Ana Castro BaladoAna Castro Balado
Ana Castro Balado
SGSePkLin Study Group
SePkLin Study Group
Introduction Linezolid is a broadly used antibiotic to treat complicated infections caused by gram-positive bacteria. Therapeutic drug monitoring of linezolid concentrations is recommended to maximise its efficacy and safety, mainly haematological toxicity. Different pharmacokinetic/pharmacodynamic targets have been proposed to improve linezolid exposure: the ratio of the area under the concentration–time curve during a 24-hour period to minimum inhibitory concentration (MIC) between 80 and 120; percentage of time that the drug concentration remains above the MIC during a dosing interval greater than 85% and the trough concentration between 2 and 7 mg/L. This clinical trial aims to evaluate the safety, efficacy and the clinical and economic utility of personalised dosing of linezolid using Bayesian forecasting methods to attain pharmacokinetic/pharmacodynamic targets, known as model-informed precision dosing. Methods and analysis This is a pragmatic, multicentre, randomised, parallel, controlled, phase IV and low intervention trial. Participants will be randomly assigned 1:1 to each group (n=346 per group). Control group will receive the standard dose of linezolid. Intervention group will receive personalised dosage of linezolid based on pharmacokinetic–pharmacodynamic adjustments. The primary outcome will be the incidence of thrombocytopenia in both groups. Ethics and dissemination This protocol was approved by the Ethical Committee of the Investigation with Medicines of Galicia (code 2022/140) and authorised by the Spanish Agency for Medicines and Medical Devices. The trial is implemented in accordance with the Declaration of Helsinki and the international ethical and scientific quality standard, the Good Clinical Practice. The results will be published in peer-reviewed journals. Trial registration number EudraCT registration code: 2022-000144-30.